论文部分内容阅读
本文旨在报道用组织型重组纤维蛋白溶酶原激活剂((rt-PA)治疗急性心肌梗塞病人.其优点是可避免全身性纤溶状态,从而减少严重出血的可能性.
This article aims to report the use of tissue-type recombinant plasminogen activator ((rt-PA) in patients with acute myocardial infarction with the advantage of avoiding systemic fibrinolytic conditions, thereby reducing the possibility of severe bleeding.